Corbus Pharmaceuticals Holdings, Inc. Stock

Equities

CRBP

US21833P3010

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
36.53 USD -1.70% Intraday chart for Corbus Pharmaceuticals Holdings, Inc. -8.68% +504.80%
Sales 2024 * - Sales 2025 * - Capitalization 390M
Net income 2024 * -53M Net income 2025 * -65M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-7.02 x
P/E ratio 2025 *
-7.13 x
Employees 19
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.31%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Corbus Pharmaceuticals Holdings, Inc.

1 day-1.70%
1 week-8.68%
Current month-6.91%
1 month-12.23%
3 months+427.89%
6 months+508.83%
Current year+504.80%
More quotes
1 week
35.19
Extreme 35.19
45.00
1 month
33.24
Extreme 33.2398
45.00
Current year
5.67
Extreme 5.6654
49.87
1 year
3.03
Extreme 3.0334
49.87
3 years
2.11
Extreme 2.11
68.70
5 years
2.11
Extreme 2.11
293.40
10 years
2.11
Extreme 2.11
323.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 13-06-30
Director of Finance/CFO 66 14-04-10
Chief Tech/Sci/R&D Officer 50 Feb. 27
Members of the board TitleAgeSince
Chairman 74 13-12-31
Director/Board Member 75 14-07-31
Chief Executive Officer 49 13-06-30
More insiders
Date Price Change Volume
24-04-18 36.53 -1.70% 127,838
24-04-17 37.16 -9.63% 419,840
24-04-16 41.12 -3.75% 353,278
24-04-15 42.72 +4.58% 347,537
24-04-12 40.85 +2.13% 291,783

Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT

More quotes
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
36.53 USD
Average target price
55 USD
Spread / Average Target
+50.56%
Consensus